Pacira Pharmaceuticals Inc. (PCRX) Stock Price Up 8.8%
Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) shares rose 8.8% on Wednesday . The company traded as high as $39.74 and last traded at $38.84, with a volume of 1,202,474 shares changing hands. The stock had previously closed at $35.69.
PCRX has been the topic of a number of recent research reports. Wedbush restated an “outperform” rating and set a $113.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, March 23rd. Mizuho initiated coverage on shares of Pacira Pharmaceuticals in a report on Tuesday, April 19th. They set a “buy” rating and a $79.00 price target on the stock. Canaccord Genuity restated a “buy” rating on shares of Pacira Pharmaceuticals in a report on Wednesday, April 20th. Zacks Investment Research upgraded shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, April 26th. Finally, TheStreet downgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 2nd. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the stock. Pacira Pharmaceuticals has an average rating of “Hold” and an average price target of $78.15.
The firm’s market cap is $1.43 billion. The firm’s 50 day moving average is $39.86 and its 200 day moving average is $52.12.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Monday, May 2nd. The company reported $0.15 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.07 by $0.08. During the same period last year, the firm posted $0.27 earnings per share. The company earned $65.50 million during the quarter, compared to analysts’ expectations of $67.11 million. Pacira Pharmaceuticals’s quarterly revenue was up 12.3% compared to the same quarter last year. Equities research analysts anticipate that Pacira Pharmaceuticals Inc. will post $0.36 earnings per share for the current year.
In related news, CAO Kristen Marie Williams sold 600 shares of the business’s stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $47.20, for a total value of $28,320.00. Following the sale, the chief accounting officer now directly owns 6,900 shares in the company, valued at approximately $325,680. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Lauren Bullaro Riker sold 938 shares of the business’s stock in a transaction dated Tuesday, June 7th. The shares were sold at an average price of $47.66, for a total value of $44,705.08. Following the completion of the sale, the vice president now owns 5,945 shares in the company, valued at $283,338.70. The disclosure for this sale can be found here.
Other large investors have recently made changes to their positions in the company. Russell Frank Co boosted its stake in shares of Pacira Pharmaceuticals by 934.0% in the fourth quarter. Russell Frank Co now owns 82,720 shares of the company’s stock worth $6,371,000 after buying an additional 74,720 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Pacira Pharmaceuticals by 8.0% in the fourth quarter. Rhumbline Advisers now owns 42,471 shares of the company’s stock worth $3,261,000 after buying an additional 3,160 shares in the last quarter. TD Asset Management Inc. boosted its stake in shares of Pacira Pharmaceuticals by 1.8% in the fourth quarter. TD Asset Management Inc. now owns 74,700 shares of the company’s stock worth $5,736,000 after buying an additional 1,300 shares in the last quarter. California Public Employees Retirement System boosted its stake in shares of Pacira Pharmaceuticals by 182.5% in the fourth quarter. California Public Employees Retirement System now owns 77,400 shares of the company’s stock worth $5,944,000 after buying an additional 50,000 shares in the last quarter. Finally, Engineers Gate Manager LP purchased a new stake in shares of Pacira Pharmaceuticals during the fourth quarter worth about $1,005,000.
Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.